Could a diabetes drug and immune therapy slow Alzheimer's? new trial launches
NCT ID NCT07651319
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether combining interleukin-2 (IL-2) with semaglutide (a diabetes drug) can safely reduce harmful inflammation in the brains of people with Alzheimer's disease. The study will enroll 30 adults aged 50–86 with mild-to-moderate Alzheimer's. Participants will receive either placebo, IL-2 alone, or IL-2 plus semaglutide for six months. Researchers will monitor safety, immune cell changes, and markers of brain health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Interleukin-2 (IL-2) and semaglutide
What this could lead to
If successful, this could point toward a new treatment that slows Alzheimer's progression by calming brain inflammation.
What could go wrong
This is an early, small trial (30 people) focused on safety. The combination may not show clear benefits, and side effects from the drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DEMENTIA (AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Research Institute
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••